Literature DB >> 30062011

Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma.

Roberto W Dal Negro1, Luca Bonadiman1, Paola Turco2.   

Abstract

[This corrects the article DOI: 10.1186/s40248-018-0131-x.].

Entities:  

Year:  2018        PMID: 30062011      PMCID: PMC6058386          DOI: 10.1186/s40248-018-0144-5

Source DB:  PubMed          Journal:  Multidiscip Respir Med        ISSN: 1828-695X


Correction to: Multidisciplinary Respiratory Medicine (2018) 13:18 DOI: 10.1186/s40248-018-0131-x

After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Fig. 3 and Fig. 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27) after 3; 1.40 (0.27) after 6, and 1.45 days (0.58) after twelve months (Anova: p = 0.11) in group A, while the corresponding duration in group B was 3.35 (0.63) at baseline; 0.60 (0.19) after 3; 1.10 (0.21) after 6, and 0.83 days (0.39) after 12 months (Anova; p <0.001), respectively.” In addition at pag. 7 Fig. 5 entitled “Changes in mean duration of inactivity/p. over 12 months” must be substituted with the new Fig. 5 because there is a mistake regarding anova p = 0.11 and consequently in the whole image. This Correction shows the revised Fig. 5. The original article has been updated.
Fig. 5

Changes in mean duration of inactivity/p. over 12 months

Changes in mean duration of inactivity/p. over 12 months
  1 in total

1.  Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma.

Authors:  Roberto W Dal Negro; Luca Bonadiman; Paola Turco
Journal:  Multidiscip Respir Med       Date:  2018-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.